Details of Disease

General Information of Disease (ID: DISLWTG2)

Disease Name Psoriatic arthritis
Synonyms psoriatic arthritis, susceptibility to, 1; psoriatic arthropathy; susceptibility to psoriatic arthritis; psoriatic arthritis, susceptibility to; arthropathic psoriasis; arthritis psoriatica
Disease Class FA21: Psoriatic arthritis
Definition Joint inflammation associated with psoriasis.
Disease Hierarchy
DIS6SVEE: Syndromic disease
DIST1YEL: Arthritis
DISTSB4J: Rheumatoid arthritis
DISLWTG2: Psoriatic arthritis
ICD Code
ICD-11
ICD-11: FA21
ICD-9
ICD-9: 696
Expand ICD-11
'FA21
Expand ICD-10
'L40.5; 'M07; 'M07.0; 'M07.1; 'M07.3; 'M07.6
Expand ICD-9
696
Disease Identifiers
MONDO ID
MONDO_0011849
MESH ID
D015535
UMLS CUI
C0003872
MedGen ID
2077
Orphanet ID
40050
SNOMED CT ID
156370009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 23 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Adalimumab DMQMV1B Approved Antibody [1]
Apremilast DMTWS9E Approved Small molecular drug [2]
Belumosudil DM548TK Approved NA [3]
Betamethasone DMAHJEF Approved Small molecular drug [4]
Bimekizumab DMR9TF1 Approved NA [5]
Cortisone Acetate DMG8K57 Approved Small molecular drug [6]
Dexamethasone DMMWZET Approved Small molecular drug [7]
Etanercept DMCV109 Approved Monoclonal antibody [8]
Golimumab DMHZV7X Approved Antibody [9]
Hydrocortisone DMGEMB7 Approved Small molecular drug [10]
Infliximab DMH7OIA Approved Antibody [9]
Ixekizumab DMXW92T Approved Monoclonal antibody [11]
Leflunomide DMR8ONJ Approved Small molecular drug [12]
Methylprednisolone DM4BDON Approved Small molecular drug [13]
Prednisolone DMQ8FR2 Approved Small molecular drug [14]
Prednisone DM2HG4X Approved Small molecular drug [15]
Risankizumab DMM32GT Approved NA [5]
Secukinumab DMYXT2U Approved Monoclonal antibody [16]
Talazoparib DM1KS78 Approved Small molecular drug [17]
Teriflunomide DMQ2FKJ Approved Small molecular drug [18]
Triamcinolone DM98IXF Approved Small molecular drug [19]
Upadacitinib DM32B5U Approved NA [5]
Ustekinumab DMHTYK3 Approved Antibody [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 Drug(s)
This Disease is Treated as An Indication in 16 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABP 654 DM0GXWT Phase 3 Monoclonal antibody [21]
BI 655066 DMBH4FL Phase 3 Antibody [3]
GP-2017 DMR670F Phase 3 NA [5]
SB2 DMS1PFA Phase 3 NA [3]
Sivelestat DM6BZCV Phase 3 Small molecular drug [3]
Tremfya DMEQ2XA Phase 3 NA [5]
VAL BRO 03 DMU4AT2 Phase 3 NA [3]
Vanadate DMQL0KF Phase 3 Small molecular drug [3]
ABT-122 DM23UQ9 Phase 2 Monoclonal antibody [3]
ALD-518 DMPWSBL Phase 2 NA [22]
NDI-034858 DM2FJE7 Phase 2 Small molecule [23]
Neihulizumab DMUPZFO Phase 2 NA [3]
Zunsemetinib DMNFNK7 Phase 2 Small molecule [24]
Debio-0824 DMV401D Phase 1b/2a NA [25]
ABP-710 DMIMVBQ Phase 1 NA [5]
GSK3050002 DM4ZK6G Phase 1 NA [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GP2015 DMVYFTQ Application submitted NA [3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 51 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CYP21A2 TTP4GLG Limited Genetic Variation [26]
DDR1 TTI1FPZ Limited Genetic Variation [26]
IL23A TTC1GLB Limited Biomarker [27]
NOS2 TTF10I9 Limited Altered Expression [28]
KIR3DL2 TTQH3N0 Disputed Genetic Variation [29]
MCAM TTHRE05 Disputed Altered Expression [30]
PCCA TT1JDE3 Disputed Genetic Variation [31]
PCCB TT5LURU Disputed Biomarker [31]
IL12B TTGW72V moderate Genetic Variation [32]
LTA TTP73TM moderate Genetic Variation [33]
RUNX2 TTD6SZ8 moderate Biomarker [34]
ACR TTAHE2N Strong Genetic Variation [35]
ASPA TT6TLZP Strong Biomarker [36]
ATRAID TTFLIKM Strong Biomarker [37]
BMP4 TTD3BSX Strong Biomarker [38]
CAMP TTULOB6 Strong Altered Expression [39]
CD248 TTYJWT7 Strong Altered Expression [40]
CD83 TTT9MRQ Strong Altered Expression [41]
CYP11B2 TT9MNE2 Strong Biomarker [42]
DNAJB1 TTPXAWS Strong Genetic Variation [43]
EIF2AK1 TTRUJBV Strong Genetic Variation [44]
ENPEP TT9PBIL Strong Biomarker [45]
ERAP2 TTVGS1C Strong Genetic Variation [46]
FGG TTR31L7 Strong Genetic Variation [47]
GPR55 TTNET8J Strong Altered Expression [48]
HLA-A TTHONFT Strong Biomarker [49]
IL13 TT0GVCH Strong Genetic Variation [50]
IL17F TT2B6PS Strong Genetic Variation [51]
IL23R TT6H4QR Strong Altered Expression [52]
IL25 TTVMO5W Strong Altered Expression [51]
IL37 TTQTX98 Strong Biomarker [53]
ITGA1 TTPERWV Strong Biomarker [54]
KIF5A TTCJPAH Strong Genetic Variation [55]
LILRB2 TTHC6XU Strong Altered Expression [56]
MAP4K1 TTSHWUP Strong Altered Expression [57]
MMP15 TTNSTO3 Strong Altered Expression [58]
NFKBIA TTSHAEB Strong Genetic Variation [59]
NR4A2 TT9HKN3 Strong Biomarker [60]
PDE4A TTZ97H5 Strong Biomarker [61]
PDE4B TTVIAT9 Strong Altered Expression [62]
PPARGC1B TTKSQ3W Strong Altered Expression [63]
PRLR TTBPXMA Strong Biomarker [64]
PRMT3 TTL4XSQ Strong Biomarker [65]
REL TT1ZCTH Strong Biomarker [66]
RORC TTGV6LY Strong Biomarker [67]
TNFAIP3 TT5W0IO Strong Genetic Variation [68]
UCP3 TT12RJK Strong Biomarker [69]
UGCG TTPHEX3 Strong Biomarker [70]
ERAP1 TT60XFL Definitive Genetic Variation [46]
IL22 TTLDX4N Definitive Genetic Variation [71]
IL9 TT0JTFD Definitive Biomarker [72]
------------------------------------------------------------------------------------
⏷ Show the Full List of 51 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC16A10 DTPAQJO Limited Genetic Variation [26]
ABCC11 DTWN7FC Strong Biomarker [73]
SLC22A5 DT3HUVD Strong Genetic Variation [74]
------------------------------------------------------------------------------------
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
PGM1 DEA3VM1 Strong Biomarker [75]
SMOX DEOH5V3 Strong Biomarker [76]
------------------------------------------------------------------------------------
This Disease Is Related to 84 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BAG6 OT4Z0S2U Limited Genetic Variation [26]
C1orf141 OTASPHL0 Limited Genetic Variation [26]
CTNNA3 OT9Z0P1E Limited Genetic Variation [68]
GABBR1 OTU5A52J Limited Genetic Variation [26]
HLA-F OT76CM19 Limited Genetic Variation [26]
INSL6 OTF8OJQC Limited Genetic Variation [68]
MFSD4B OTHHKWRT Limited Genetic Variation [26]
MRPS18B OT1K9PFX Limited Genetic Variation [26]
POU5F1 OTDHHN7O Limited Genetic Variation [26]
PPP1R10 OT7GE3BN Limited Genetic Variation [26]
REV3L OT0OP8EJ Limited Genetic Variation [26]
TNXB OTVBWAV5 Limited Genetic Variation [26]
TRAF3IP2 OTLLZERL Limited Genetic Variation [26]
AFF3 OTR0705Z Disputed Genetic Variation [55]
CFL1 OTT6D5MH Disputed Biomarker [37]
ELOVL6 OTB26UJJ Disputed Genetic Variation [77]
KIR3DL1 OTPOSXFX Disputed Biomarker [78]
FBXL19 OTGDHPOE moderate Genetic Variation [50]
MEFV OTRJ6S6K moderate Genetic Variation [79]
A1CF OTJBKFA1 Strong Biomarker [36]
ACAD8 OT3JI5GB Strong Biomarker [80]
ACADM OTA4P0FC Strong Genetic Variation [69]
ADAM11 OTPTVW5W Strong Biomarker [81]
ADAMTS9 OTV3Q0DS Strong Genetic Variation [82]
ANKRD6 OTM86B04 Strong Genetic Variation [83]
CAMK4 OT47RDGV Strong Biomarker [84]
CCRL2 OT5PX0RX Strong Genetic Variation [44]
CD68 OTOYEY3J Strong Biomarker [60]
CDAN1 OTCVZRG6 Strong Biomarker [85]
DCTN5 OTESGJ1N Strong Biomarker [86]
DLAT OT9LBJVN Strong Altered Expression [87]
EEF1E1 OTRA6XOB Strong Biomarker [37]
EID1 OT3OI5H4 Strong Biomarker [88]
ERAL1 OTSH78HD Strong Biomarker [89]
FGA OTMIHY80 Strong Biomarker [90]
FIP1L1 OTF91GTL Strong Biomarker [91]
FLG OTE9QDV6 Strong Genetic Variation [92]
GZMA OT43R33L Strong Biomarker [67]
HCP5 OTV0YRI8 Strong Genetic Variation [93]
HEMK1 OTSHNL5K Strong Biomarker [84]
HLA-DMB OT17HGXJ Strong Genetic Variation [94]
HMGN2 OTN20MEF Strong Biomarker [95]
IFI16 OT4SPU0U Strong Biomarker [96]
IFNLR1 OTWWWK45 Strong Genetic Variation [97]
IL12RB1 OTM1IJO2 Strong Genetic Variation [98]
IL1F10 OTJAASGC Strong Biomarker [99]
IL9R OTILCLXA Strong Biomarker [72]
IMPACT OTQ923OB Strong Genetic Variation [100]
JAM2 OTHVJJRJ Strong Biomarker [66]
KIF3A OTMUBSSK Strong Biomarker [101]
LAMTOR1 OTIBJBW9 Strong Biomarker [37]
LCE3A OTOJUELU Strong Genetic Variation [68]
MAFK OTZJUE4P Strong Biomarker [37]
MAGI1 OTMV4ASV Strong Genetic Variation [82]
MICB OTS2DVDW Strong Genetic Variation [102]
MOS OTNMQPFJ Strong Genetic Variation [103]
MYOM2 OTD2UOXW Strong Biomarker [104]
NLRC3 OTWLLFFN Strong Biomarker [105]
NOC2L OTNT7R33 Strong Biomarker [106]
NOX3 OT0FFJH8 Strong Altered Expression [107]
PHEX OTG7N3J7 Strong Genetic Variation [108]
PITPNM1 OTIUYAG5 Strong Biomarker [106]
PLCL2 OTK5FDF6 Strong Genetic Variation [55]
POLH OTN07WXU Strong Posttranslational Modification [109]
PSORS1C1 OT9HK436 Strong Biomarker [110]
RFC2 OTJ9N6BD Strong Biomarker [111]
RHCE OTS18IZ5 Strong Biomarker [91]
RHOD OTALMEIN Strong Altered Expression [112]
ROPN1L OTRWZJ68 Strong Biomarker [36]
RPS2 OTSMTZVB Strong Biomarker [113]
RPS4X OTIH80EK Strong Biomarker [113]
SFTPA2 OT6SFOMU Strong Biomarker [114]
TAB3 OT1ECMDL Strong Altered Expression [84]
TNFAIP8L2 OTII0RM0 Strong Biomarker [115]
TNIP1 OTRAOTEW Strong Genetic Variation [26]
TPPP2 OTI3WA6X Strong Biomarker [37]
TRAF5 OTSBTLO0 Strong Biomarker [111]
TRIM8 OTS6JFR0 Strong Biomarker [116]
CHPT1 OT4FJ0K3 Definitive Biomarker [69]
CPT1A OTI862QH Definitive Biomarker [69]
CPT2 OTIN6G20 Definitive Biomarker [69]
IL17RA OTVVI8ER Definitive Biomarker [117]
KLRB1 OTQ2959Y Definitive Altered Expression [67]
MTX1 OTLSDNZO Definitive Biomarker [118]
------------------------------------------------------------------------------------
⏷ Show the Full List of 84 DOT(s)

References

1 Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227-1239.
2 Apremilast FDA Label
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Betamethasone FDA Label
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Cortisone acetate FDA Label
7 Dexamethasone FDA Label
8 Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol. 2019 Jul;71(7):1112-1124.
9 Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
10 Hydrocortisone FDA Label
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541).
12 Leflunomide FDA Label
13 Methylprednisolone FDA Label
14 Prednisolone FDA Label
15 Prednisone FDA Label
16 ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313).
18 Teriflunomide FDA Label
19 Triamcinolone FDA Label
20 Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19;323(19):1945-1960.
21 ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health.
22 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
23 ClinicalTrials.gov (NCT05153148) A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. U.S.National Institutes of Health.
24 ClinicalTrials.gov (NCT05511519) A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis. U.S.National Institutes of Health.
25 ClinicalTrials.gov (NCT02446340) Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers. U.S. National Institutes of Health.
26 Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.Ann Rheum Dis. 2019 Mar;78(3):e214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14.
27 Tissue-Resident Memory T Cells: Sequestered Immune Sensors and Effectors of Inflammation in Spondyloarthritis.Arthritis Rheumatol. 2020 Mar;72(3):379-382. doi: 10.1002/art.41172. Epub 2020 Feb 4.
28 Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes.Sci Adv. 2018 May 16;4(5):eaas9864. doi: 10.1126/sciadv.aas9864. eCollection 2018 May.
29 Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis.Rheumatology (Oxford). 2014 Feb;53(2):233-9. doi: 10.1093/rheumatology/ket296. Epub 2013 Oct 31.
30 Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon- by CD4(+) T cells in patients with inflammatory arthritis.Clin Exp Immunol. 2015 Mar;179(3):378-91. doi: 10.1111/cei.12434.
31 Seventeen Novel Mutations in PCCA and PCCB Genes in Indian Propionic Acidemia Patients, and Their Outcomes.Genet Test Mol Biomarkers. 2016 Jul;20(7):373-82. doi: 10.1089/gtmb.2016.0017. Epub 2016 May 26.
32 Association of TNF, IL12, and IL23 gene polymorphisms and psoriatic arthritis: meta-analysis.Expert Rev Clin Immunol. 2019 Mar;15(3):303-313. doi: 10.1080/1744666X.2019.1564039. Epub 2019 Jan 24.
33 Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis.J Rheumatol. 2004 Nov;31(11):2230-5.
34 Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.Am J Respir Crit Care Med. 2016 Nov 15;194(10):1273-1285. doi: 10.1164/rccm.201512-2380OC.
35 Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.Arthritis Care Res (Hoboken). 2020 Jun;72(6):806-813. doi: 10.1002/acr.23905. Epub 2020 May 15.
36 High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?.Semin Arthritis Rheum. 2018 Dec;48(3):538-546. doi: 10.1016/j.semarthrit.2018.03.018. Epub 2018 Mar 29.
37 "Invivo self-assembled" nanoprobes for optimizing autophagy-mediated chemotherapy.Biomaterials. 2017 Oct;141:199-209. doi: 10.1016/j.biomaterials.2017.06.042. Epub 2017 Jun 30.
38 Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol. 2010 Feb;37(2):246-56. doi: 10.3899/jrheum.090167. Epub 2009 Dec 15.
39 Identification of Novel Autoantibodies Associated With Psoriatic Arthritis.Arthritis Rheumatol. 2019 Jun;71(6):941-951. doi: 10.1002/art.40830. Epub 2019 Apr 6.
40 CD248 and its cytoplasmic domain: a therapeutic target for arthritis.Arthritis Rheum. 2010 Dec;62(12):3595-606. doi: 10.1002/art.27701.
41 Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.Arthritis Res Ther. 2006;8(1):R15. doi: 10.1186/ar1864.
42 Aldosterone-Producing Cell Clusters in Normal and Pathological States.Horm Metab Res. 2017 Dec;49(12):951-956. doi: 10.1055/s-0043-122394. Epub 2017 Dec 4.
43 Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis.J Transl Med. 2019 Nov 14;17(1):375. doi: 10.1186/s12967-019-2128-4.
44 Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1*WWCC in psoriasis.Acta Derm Venereol. 2007;87(2):127-34. doi: 10.2340/00015555-0184.
45 Ultrasound elastography score and strain index in different parathyroid lesions.Endocr Connect. 2019 Dec;8(12):1579-1590. doi: 10.1530/EC-19-0443.
46 ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population.Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):123-129. doi: 10.1007/s00005-016-0444-4. Epub 2017 Jan 12.
47 Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio.J Thromb Haemost. 2007 Jun;5(6):1243-9. doi: 10.1111/j.1538-7836.2007.02566.x.
48 Pathophysiological Alterations of Redox Signaling and Endocannabinoid System in Granulocytes and Plasma of Psoriatic Patients.Cells. 2018 Oct 6;7(10):159. doi: 10.3390/cells7100159.
49 HLA-A*01:01 in MHC is associated with psoriatic arthritis in Chinese Han population.Arch Dermatol Res. 2019 May;311(4):277-285. doi: 10.1007/s00403-019-01902-3. Epub 2019 Mar 2.
50 What have genome-wide studies told us about psoriatic arthritis?.Curr Rheumatol Rep. 2012 Aug;14(4):364-8. doi: 10.1007/s11926-012-0255-5.
51 Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity.Br J Dermatol. 2020 Jan;182(1):130-137. doi: 10.1111/bjd.18008. Epub 2019 Jul 17.
52 Functional significance of MAIT cells in psoriatic arthritis.Cytokine. 2020 Jan;125:154855. doi: 10.1016/j.cyto.2019.154855. Epub 2019 Sep 18.
53 The parallel paradigm between intestinal transplant inflammation and inflammatory bowel disease.Curr Opin Organ Transplant. 2019 Apr;24(2):207-211. doi: 10.1097/MOT.0000000000000615.
54 Synovial VLA-1+ T cells display an oligoclonal and partly distinct repertoire in rheumatoid and psoriatic arthritis.Clin Immunol. 2008 Jul;128(1):75-84. doi: 10.1016/j.clim.2008.02.014. Epub 2008 May 5.
55 Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort.Ann Rheum Dis. 2012 Aug;71(8):1350-4. doi: 10.1136/annrheumdis-2011-200802. Epub 2012 Feb 10.
56 Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.PLoS One. 2014 Mar 27;9(3):e92018. doi: 10.1371/journal.pone.0092018. eCollection 2014.
57 MAP4K Family Kinases in Immunity and Inflammation. Adv Immunol. 2016;129:277-314.
58 Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.J Rheumatol. 2002 Jan;29(1):107-17.
59 Identification of a Single Nucleotide Polymorphism in NFKBIA with Different Effects on Psoriatic Arthritis and Cutaneous Psoriasis in China.Acta Derm Venereol. 2019 Jan 1;99(1):84-88. doi: 10.2340/00015555-3027.
60 Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. Mol Immunol. 2009 Oct;46(16):3345-57. doi: 10.1016/j.molimm.2009.07.019. Epub 2009 Sep 3.
61 Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.J Clin Med. 2019 Mar 22;8(3):398. doi: 10.3390/jcm8030398.
62 Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B.J Autoimmun. 2019 Jan;96:86-93. doi: 10.1016/j.jaut.2018.08.008. Epub 2018 Sep 1.
63 PGC-1 suppresses saturated fatty acid-induced macrophage inflammation by inhibiting TAK1 activation.IUBMB Life. 2016 Feb;68(2):145-55. doi: 10.1002/iub.1470. Epub 2016 Jan 9.
64 Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis.Front Immunol. 2017 Jun 23;8:720. doi: 10.3389/fimmu.2017.00720. eCollection 2017.
65 PRMT3 regulates hepatic lipogenesis through direct interaction with LXR.Diabetes. 2015 Jan;64(1):60-71. doi: 10.2337/db13-1394. Epub 2014 Sep 3.
66 Human leukocyte antigen (HLA)-C polymorphisms are associated with a decreased risk of rheumatoid arthritis.Mol Biol Rep. 2014 Jun;41(6):4103-8. doi: 10.1007/s11033-014-3280-9. Epub 2014 Feb 25.
67 Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis.Arthritis Rheumatol. 2020 Mar;72(3):435-447. doi: 10.1002/art.41156. Epub 2020 Feb 4.
68 Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28.
69 Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells.Nutrients. 2019 Nov 17;11(11):2806. doi: 10.3390/nu11112806.
70 Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation.Atherosclerosis. 2018 Apr;271:214-222. doi: 10.1016/j.atherosclerosis.2018.03.004. Epub 2018 Mar 2.
71 Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.PLoS One. 2019 Feb 19;14(2):e0212043. doi: 10.1371/journal.pone.0212043. eCollection 2019.
72 IL-9 receptor: Regulatory role on FLS and pannus formation.Cytokine. 2018 Nov;111:58-62. doi: 10.1016/j.cyto.2018.08.001. Epub 2018 Aug 14.
73 MRP8/14 enhances corneal susceptibility to Pseudomonas aeruginosa Infection by amplifying inflammatory responses.Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):1227-34. doi: 10.1167/iovs.12-10172.
74 Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis.Arthritis Rheum. 2005 Nov;52(11):3596-602. doi: 10.1002/art.21393.
75 Red cell enzyme types in rheumatic diseases.Hum Hered. 1985;35(2):107-10. doi: 10.1159/000153525.
76 Pseudomonas aeruginosa induces cellular senescence in lung tissue at the early stage of two-hit septic mice.Pathog Dis. 2018 Dec 1;76(9). doi: 10.1093/femspd/ftz001.
77 Association of the late cornified envelope-3 genes with psoriasis and psoriatic arthritis: a systematic review.J Genet Genomics. 2015 Feb 20;42(2):49-56. doi: 10.1016/j.jgg.2015.01.001. Epub 2015 Jan 10.
78 Association of variably expressed KIR3dl1 alleles with psoriatic disease.Clin Rheumatol. 2017 Oct;36(10):2261-2266. doi: 10.1007/s10067-017-3784-5. Epub 2017 Aug 11.
79 Juvenile psoriatic arthritis carrying familial Mediterranean fever gene mutations in a 14-year-old Turkish girl.J Dermatol. 2007 May;34(5):344-8. doi: 10.1111/j.1346-8138.2007.00285.x.
80 The Paradoxical Induction of Crohns Disease Following Treatment of Psoriatic Arthritis With Etanercept.J Drugs Dermatol. 2019 Aug 1;18(8):832-834.
81 Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.Cytokine. 2010 Jan;49(1):24-9. doi: 10.1016/j.cyto.2009.10.005. Epub 2009 Nov 25.
82 A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk.Ann Rheum Dis. 2015 Oct;74(10):1875-81. doi: 10.1136/annrheumdis-2014-207190. Epub 2015 May 19.
83 Variants of the ankyrin repeat domain 6 gene (ANKRD6) and muscle and physical activity phenotypes among European-derived American adults.J Strength Cond Res. 2012 Jul;26(7):1740-8. doi: 10.1519/JSC.0b013e31825c2bef.
84 Evidence for a Role of TGF--Activated Kinase 1 and MAP3K7 Binding Protein 3 in Peanut-Specific T-Cell Responses.Int Arch Allergy Immunol. 2019;179(1):10-16. doi: 10.1159/000496438. Epub 2019 Mar 20.
85 Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.Ann Rheum Dis. 2017 Apr;76(4):708-711. doi: 10.1136/annrheumdis-2016-210283. Epub 2016 Oct 4.
86 DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.Clin Respir J. 2016 Nov;10(6):777-783. doi: 10.1111/crj.12288. Epub 2015 Apr 15.
87 Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.Mol Med. 2005 Jan-Dec;11(1-12):21-9. doi: 10.2119/2006-00003.Gulko.
88 Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?.Adv Rheumatol. 2019 Nov 14;59(1):49. doi: 10.1186/s42358-019-0096-2.
89 Leflunomide treatment in juvenile idiopathic arthritis.Rheumatol Int. 2019 Sep;39(9):1615-1619. doi: 10.1007/s00296-019-04385-7. Epub 2019 Jul 20.
90 Serum peptides as putative modulators of inflammation in psoriasis.J Dermatol Sci. 2017 Jul;87(1):36-49. doi: 10.1016/j.jdermsci.2017.03.014. Epub 2017 Mar 27.
91 Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study.Postgrad Med. 2018 Jan;130(1):137-141. doi: 10.1080/00325481.2018.1399774. Epub 2017 Nov 3.
92 Loss-of-function variants of the filaggrin gene are not major susceptibility factors for psoriasis vulgaris or psoriatic arthritis in German patients.J Invest Dermatol. 2007 Jun;127(6):1367-70. doi: 10.1038/sj.jid.5700720. Epub 2007 Jan 25.
93 Genomic dissection of population substructure of Han Chinese and its implication in association studies.Am J Hum Genet. 2009 Dec;85(6):762-74. doi: 10.1016/j.ajhg.2009.10.015.
94 HLA-DMA and HLA-DMB genotyping in patients with rheumatic diseases.Kaohsiung J Med Sci. 1999 May;15(5):263-7.
95 Nuclear protein HMGN2 attenuates pyocyanin-induced oxidative stress via Nrf2 signaling and inhibits Pseudomonas aeruginosa internalization in A549 cells.Free Radic Biol Med. 2017 Jul;108:404-417. doi: 10.1016/j.freeradbiomed.2017.04.007. Epub 2017 Apr 10.
96 Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis.Clin Exp Immunol. 2020 Jan;199(1):88-96. doi: 10.1111/cei.13376. Epub 2019 Oct 15.
97 Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris.Br J Dermatol. 2013 May;168(5):1060-5. doi: 10.1111/bjd.12142.
98 Association study in Romanians confirms IL23A gene haplotype block rs2066808/rs11171806 as conferring risk to psoriatic arthritis.Cytokine. 2013 Jul;63(1):67-73. doi: 10.1016/j.cyto.2013.04.013. Epub 2013 May 11.
99 IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.Int J Mol Sci. 2019 Mar 13;20(6):1257. doi: 10.3390/ijms20061257.
100 Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.Ann Rheum Dis. 2017 Feb;76(2):418-421. doi: 10.1136/annrheumdis-2016-209511. Epub 2016 Jul 25.
101 KIF3A and IL-4 are disease-specific biomarkers for psoriatic arthritis susceptibility.Oncotarget. 2017 Sep 8;8(56):95401-95411. doi: 10.18632/oncotarget.20727. eCollection 2017 Nov 10.
102 MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis.J Rheumatol. 2002 May;29(5):973-8.
103 The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study).J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1499-1506. doi: 10.1111/jdv.14865. Epub 2018 Mar 5.
104 Significance of antibodies to streptococcal M protein in psoriatic arthritis and their association with HLA-A*0207.Tissue Antigens. 1996 Dec;48(6):645-50. doi: 10.1111/j.1399-0039.1996.tb02687.x.
105 NLRC3 promotes host resistance against Pseudomonas aeruginosa-induced keratitis by promoting the degradation of IRAK1.Int J Mol Med. 2017 Sep;40(3):898-906. doi: 10.3892/ijmm.2017.3077. Epub 2017 Jul 20.
106 Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy.Theranostics. 2018 Nov 15;8(21):6025-6034. doi: 10.7150/thno.26607. eCollection 2018.
107 Pterostilbene reverses palmitic acid mediated insulin resistance in HepG2 cells by reducing oxidative stress and triglyceride accumulation.Free Radic Res. 2019 Jul;53(7):815-827. doi: 10.1080/10715762.2019.1635252. Epub 2019 Jul 10.
108 PHEX 3'-UTR c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets.J Bone Miner Res. 2015 Jan;30(1):137-43. doi: 10.1002/jbmr.2307.
109 Improved pFastBac?donor plasmid vectors for higher protein production using the Bac-to-Bac baculovirus expression vector system.J Biotechnol. 2017 Aug 10;255:37-46. doi: 10.1016/j.jbiotec.2017.06.397. Epub 2017 Jun 20.
110 Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations.Ann Rheum Dis. 2005 Sep;64(9):1370-2. doi: 10.1136/ard.2004.031765. Epub 2005 Feb 11.
111 New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis.Arthritis Res Ther. 2012 Oct 31;14(5):226. doi: 10.1186/ar4071.
112 cMaf inducing protein inhibits cofilin? activity and alters podocyte cytoskeleton organization.Mol Med Rep. 2017 Oct;16(4):4955-4963. doi: 10.3892/mmr.2017.7156. Epub 2017 Aug 3.
113 Activatable Small-Molecule Photoacoustic Probes that Cross the Blood-Brain Barrier for Visualization of Copper(II) in Mice with Alzheimer's Disease.Angew Chem Int Ed Engl. 2019 Sep 2;58(36):12415-12419. doi: 10.1002/anie.201904047. Epub 2019 Aug 1.
114 Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages.Arthritis Rheum. 2006 Sep;54(9):2711-21. doi: 10.1002/art.22055.
115 TIPE2 Suppresses Pseudomonas aeruginosa Keratitis by Inhibiting NF-B Signaling and the Infiltration of Inflammatory Cells.J Infect Dis. 2019 Aug 9;220(6):1008-1018. doi: 10.1093/infdis/jiz246.
116 Tripartite Motif 8 (TRIM8) Positively Regulates Pro-inflammatory Responses in Pseudomonas aeruginosa-Induced Keratitis Through Promoting K63-Linked Polyubiquitination of TAK1 Protein.Inflammation. 2017 Apr;40(2):454-463. doi: 10.1007/s10753-016-0491-3.
117 The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.Clin Rev Allergy Immunol. 2018 Dec;55(3):379-390. doi: 10.1007/s12016-018-8702-3.
118 Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.Arthritis Res Ther. 2019 May 9;21(1):116. doi: 10.1186/s13075-019-1898-7.